The Challenge of Intermediate-Risk Pulmonary Embolism

医学 肺栓塞 重症监护医学 心脏病学 内科学
作者
Spencer Weintraub,Joseph You,Sean R. Wilson,Andrew Galmer
出处
期刊:American Journal of Therapeutics [Lippincott Williams & Wilkins]
卷期号:30 (2): e134-e144 被引量:1
标识
DOI:10.1097/mjt.0000000000001605
摘要

Intermediate-risk pulmonary embolism is a common disease that is associated with significant morbidity and mortality; however, a standardized treatment protocol is not well-established.Treatments available for intermediate-risk pulmonary embolisms include anticoagulation, systemic thrombolytics, catheter-directed therapies, surgical embolectomy, and extracorporeal membrane oxygenation. Despite these options, there is no clear consensus on the optimal indication and timing of these interventions.Anticoagulation remains the cornerstone of treatment for pulmonary embolism; however, over the past 2 decades, there have been advances in the safety and efficacy of catheter-directed therapies. For massive pulmonary embolism, systemic thrombolytics and, sometimes, surgical thrombectomy are considered first-line treatments. Patients with intermediate-risk pulmonary embolism are at high risk of clinical deterioration; however, it is unclear whether anticoagulation alone is sufficient. The optimal treatment of intermediate-risk pulmonary embolism in the setting of hemodynamic stability with right heart strain present is not well-defined. Therapies such as catheter-directed thrombolysis and suction thrombectomy are being investigated given their potential to offload right ventricular strain. Several studies have recently evaluated catheter-directed thrombolysis and embolectomies and demonstrated the efficacy and safety of these interventions. Here, we review the literature on the management of intermediate-risk pulmonary embolisms and the evidence behind those interventions.There are many treatments available in the management of intermediate-risk pulmonary embolism. Although the current literature does not favor 1 treatment as superior, multiple studies have shown growing data to support catheter-directed therapies as potential options for these patients. Multidisciplinary pulmonary embolism response teams remain a key feature in improving the selection of advanced therapies and optimization of care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kiki发布了新的文献求助10
1秒前
外向山雁完成签到,获得积分10
1秒前
奋斗完成签到,获得积分10
2秒前
2秒前
组蛋白完成签到 ,获得积分10
4秒前
临在完成签到,获得积分10
4秒前
siu完成签到 ,获得积分10
4秒前
5秒前
6秒前
lily发布了新的文献求助10
8秒前
核弹完成签到,获得积分10
9秒前
玄嗣完成签到 ,获得积分20
9秒前
笑点低的毛衣完成签到,获得积分10
10秒前
周子淦发布了新的文献求助30
11秒前
BK2008完成签到,获得积分10
11秒前
组蛋白发布了新的文献求助10
11秒前
LG发布了新的文献求助10
12秒前
Rui完成签到,获得积分10
13秒前
脑洞疼应助Leonard采纳,获得10
15秒前
wei_ahpu完成签到,获得积分10
15秒前
YMM完成签到,获得积分10
16秒前
mengfeidmu完成签到,获得积分10
16秒前
科研通AI6.1应助156采纳,获得10
16秒前
17秒前
17秒前
19秒前
桐桐应助LG采纳,获得10
19秒前
方鹏发布了新的文献求助10
20秒前
20秒前
orixero应助江枫采纳,获得10
21秒前
21秒前
22秒前
七月流火应助mengfeidmu采纳,获得10
23秒前
科研通AI6.4应助lu采纳,获得10
23秒前
福袋子发布了新的文献求助10
24秒前
GingerF应助Ye采纳,获得60
24秒前
佟鹭其完成签到 ,获得积分10
24秒前
小民完成签到,获得积分10
25秒前
28秒前
LXL完成签到,获得积分10
28秒前
高分求助中
Psychopathic Traits and Quality of Prison Life 1000
Chemistry and Physics of Carbon Volume 18 800
The formation of Australian attitudes towards China, 1918-1941 660
Signals, Systems, and Signal Processing 610
天津市智库成果选编 600
Forced degradation and stability indicating LC method for Letrozole: A stress testing guide 500
全相对论原子结构与含时波包动力学的理论研究--清华大学 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6451667
求助须知:如何正确求助?哪些是违规求助? 8263408
关于积分的说明 17608174
捐赠科研通 5516304
什么是DOI,文献DOI怎么找? 2903709
邀请新用户注册赠送积分活动 1880647
关于科研通互助平台的介绍 1722664